POST-TEST
Recent Advances in Medical Oncology: Targeted Therapy for Lung Cancer (Faculty Presentations)
THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.
1. Which of the following disease-free 4. Interim results of the Phase II DESTINY- survival outcomes was reported at the Lung01 study, reported at the ASCO20 plenary session of the ASCO20 Virtual Virtual meeting, evaluating the antibody- meeting from the Phase III ADAURA drug conjugate trastuzumab deruxtecan trial evaluating osimertinib as adjuvant demonstrated promising clinical activity therapy for patients with Stage IB to IIIA with a high objective response rate non-small cell lung cancer (NSCLC) with and durable responses in patients with EGFR mutations after complete tumor nonsquamous NSCLC and which of the resection? following targetable mutations? a. Statistically significant and clini- a. ALK gene rearrangements cally meaningful improvement b. EGFR mutations versus placebo c. HER2 mutations b. Trend toward statistically significant d. MET exon 14 skipping mutations improvement versus placebo e. RET fusions c. No improvement versus placebo f. ROS1 rearrangements 2. Which of the following drug types best 5. Which of the following statements is true describes the mechanism of action of with regard to CNS activity in patients the recently FDA-approved agent selper- with NSCLC, ROS-1 rearrangement and catinib for patients with metastatic brain metastases undergoing treatment NSCLC? with a ROS-1 inhibitor? a. ALK inhibitor a. Crizotinib is more efficacious b. EGFR inhibitor than entrectinib c. HER2 inhibitor b. Entrectinib is more efficacious d. MET inhibitor than crizotinib e. RET inhibitor c. Neither a nor b (these agents f. ROS1 inhibitor exhibit equivalent CNS activity)
3. Capmatinib was recently FDA approved 6. Which of the following conditions for patients with metastatic NSCLC with has been reported as an adverse which of the following genomic altera- event of special interest in patients tions? with HER2-mutated NSCLC receiving a. EGFR mutations trastuzumab deruxtecan? b. RET fusions a. New secondary cancer c. MET exon 14 skipping mutations b. Ocular toxicities c. Interstitial lung disease
7. Which of the following agents is not a selective RET inhibitor? a. Selpercatinib b. Pralsetinib c. Cabozantinib
QID 2691 POST-TEST
Recent Advances in Medical Oncology: Targeted Therapy for Lung Cancer (Faculty Presentations)
THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.
8. Emerging data evaluating targeted 10. Which of the following agents would therapy for patients with NSCLC with be most effective for a patient with EGFR exon 20 insertions demonstrate metastatic NSCLC and a TRK gene promising activity with which of the fusion? following agents? a. Trastuzumab deruxtecan a. Mobocertinib (TAK-788) b. Capmatinib b. Erlotinib c. Larotrectinib c. Afatinib
9. The Phase III ALEX study investigating the efficacy of alectinib versus crizotinib in patients with untreated advanced NSCLC with ALK rearrange- ments demonstrated which of the following progression-free survival (PFS) outcomes? a. Longer PFS with crizotinib b. Longer PFS with alectinib c. Similar PFS in both study arms
QID 2691